Search alternatives:
mg decrease » nn decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
ng decrease » nn decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
_ decrease » _ decreased (Expand Search)
500 mg » 100 mg (Expand Search), 50 mg (Expand Search), 200 mg (Expand Search)
Showing 1 - 20 results of 36 for search '(( 500 mg decrease ) OR ( 10 ((ng decrease) OR (((a decrease) OR (_ decrease)))) ))~', query time: 0.81s Refine Results
  1. 1
    PV1-treated mice exhibited a decrease in overall activation of T lymphocytes.

    PV1-treated mice exhibited a decrease in overall activation of T lymphocytes. by Pedro Henrique Papotto (791904)

    Published 2017
    Save to List
    Saved in:
  2. 2
    mPEG PV1-Fab’ treatment decreases T<sub>reg</sub> population.

    mPEG PV1-Fab’ treatment decreases T<sub>reg</sub> population. by Pedro Henrique Papotto (791904)

    Published 2017
    Save to List
    Saved in:
  3. 3
    Experimental outline.

    Experimental outline. by Melissa A. MacIver (12850566)

    Published 2022
    Save to List
    Saved in:
  4. 4
    Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (ERC) in non-dialysis chronic kidney disease (ND-CKD)

    Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (... by figshare admin karger (2628495)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Fig 5 -

    Fig 5 - by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  6. 6
    Fig 2 -

    Fig 2 - by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  7. 7
    Fig 3 -

    Fig 3 - by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  8. 8
    Fig 4 -

    Fig 4 - by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  9. 9
    Pharmacodynamic surrogates of levonorgestrel activity.

    Pharmacodynamic surrogates of levonorgestrel activity. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  10. 10
    Demographic and baseline characteristics treated population.

    Demographic and baseline characteristics treated population. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  11. 11
    Disposition of participants.

    Disposition of participants. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  12. 12
    Summary of duration of use, total dose received and adverse events.

    Summary of duration of use, total dose received and adverse events. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  13. 13
    p24 antigen production from ectocervical and vaginal tissue biopsies.

    p24 antigen production from ectocervical and vaginal tissue biopsies. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  14. 14
    Comparison of independent group soluble proteins at end of treatment.

    Comparison of independent group soluble proteins at end of treatment. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  15. 15
    <i>In vitro</i> HIV inhibitory activity of the CVL supernatant for each treatment and dosing regimen.

    <i>In vitro</i> HIV inhibitory activity of the CVL supernatant for each treatment and dosing regimen. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  16. 16
    Immune cells in ectocervical tissue at the end of treatment (visit 31) based on treatment and dosing assignment.

    Immune cells in ectocervical tissue at the end of treatment (visit 31) based on treatment and dosing assignment. by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  17. 17
    Reported impact of IVR use on menstruation (percent of participants per group reporting impact, participants may report more than one menstrual related impact).

    Reported impact of IVR use on menstruation (percent of participants per group reporting impact, participants may report more than one menstrual related impact). by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  18. 18
    Serum LNG (pg/mL) in TFV/LNG continuous IVR Users (n = 18) and in TFV/LNG interrupted IVR users IVR users (n = 17).

    Serum LNG (pg/mL) in TFV/LNG continuous IVR Users (n = 18) and in TFV/LNG interrupted IVR users IVR users (n = 17). by Andrea R. Thurman (5286005)

    Published 2022
    Save to List
    Saved in:
  19. 19
    Profibrinolytic Effect of the Epigenetic Modifier Valproic Acid in Man

    Profibrinolytic Effect of the Epigenetic Modifier Valproic Acid in Man by Ott Saluveer (641441)

    Published 2014
    “…</p><p>Methods and Results</p><p>The trial had a cross-over design where healthy men (n = 10), were treated with VPA (Ergenyl Retard) 500 mg depot tablets twice daily for 2 weeks. …”
    Save to List
    Saved in:
  20. 20
    mPEG PV1-Fab’ dampens IFN-γ production by CD4<sup>+</sup> T lymphocytes.

    mPEG PV1-Fab’ dampens IFN-γ production by CD4<sup>+</sup> T lymphocytes. by Pedro Henrique Papotto (791904)

    Published 2017
    Save to List
    Saved in:

Search Tools: